432 related articles for article (PubMed ID: 20014061)
21. [Physiopathology of the dyskinesias induced by L-dopa].
Grandas F; López-Ariztegui N
Rev Neurol; 1997 Aug; 25 Suppl 2():S151-6. PubMed ID: 9280682
[TBL] [Abstract][Full Text] [Related]
22. A trial of dextromethorphan in parkinsonian patients with motor response complications.
Verhagen Metman L; Blanchet PJ; van den Munckhof P; Del Dotto P; Natté R; Chase TN
Mov Disord; 1998 May; 13(3):414-7. PubMed ID: 9613730
[TBL] [Abstract][Full Text] [Related]
23. Memantine and reduced time with dyskinesia in Parkinson's Disease.
Wictorin K; Widner H
Acta Neurol Scand; 2016 May; 133(5):355-60. PubMed ID: 26234336
[TBL] [Abstract][Full Text] [Related]
24. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
Cersósimo MG; Scorticati MC; Micheli FE
Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
[TBL] [Abstract][Full Text] [Related]
25. Levodopa in the treatment of Parkinson's disease: current controversies.
Gerlach M; Reichmann H; Riederer P
Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
[No Abstract] [Full Text] [Related]
26. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
Montastruc JL; Schmitt L; Bagheri H
Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacological therapy of complicated Parkinson's disease].
Jiménez-Jiménez FJ; Molina JA
Rev Neurol; 1997 Aug; 25 Suppl 2():S170-9. PubMed ID: 9280685
[TBL] [Abstract][Full Text] [Related]
28. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
Facca A; Sanchez-Ramos J
Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
[No Abstract] [Full Text] [Related]
29. Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: unfavorable risk-benefit ratio.
Espay AJ; Vaughan JE; Shukla R; Gartner M; Sahay A; Revilla FJ; Duker AP
Mov Disord; 2011 Apr; 26(5):913-4. PubMed ID: 21432906
[No Abstract] [Full Text] [Related]
30. Drug treatments of levodopa-induced dyskinesias.
Vale S
Lancet; 1999 Aug; 354(9177):511. PubMed ID: 10465195
[No Abstract] [Full Text] [Related]
31. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
Bravi D; Davis TL; Mouradian MM; Chase TN
Mov Disord; 1993 Apr; 8(2):195-7. PubMed ID: 8097280
[TBL] [Abstract][Full Text] [Related]
32. [Parkinson's disease].
Yokochi M
Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):5-14. PubMed ID: 10434578
[No Abstract] [Full Text] [Related]
33. The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations.
Spieker S; Löschmann PA; Klockgether T
Mov Disord; 1999 May; 14(3):517-9. PubMed ID: 10348483
[No Abstract] [Full Text] [Related]
34. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
Merims D; Ziv I; Sherki Y; Djaldetti R; Melamed E
Neurol Neurochir Pol; 2001; 35 Suppl 3():65-8. PubMed ID: 12001656
[TBL] [Abstract][Full Text] [Related]
35. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
Del Dotto P; Pavese N; Gambaccini G; Bernardini S; Metman LV; Chase TN; Bonuccelli U
Mov Disord; 2001 May; 16(3):515-20. PubMed ID: 11391748
[TBL] [Abstract][Full Text] [Related]
36. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE
Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
[TBL] [Abstract][Full Text] [Related]
37. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.
Merims D; Ziv I; Djaldetti R; Melamed E
Lancet; 1999 May; 353(9166):1764-5. PubMed ID: 10347995
[No Abstract] [Full Text] [Related]
38. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
Zimmerman TR; Sage JI; Lang AE; Mark MH
Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
[TBL] [Abstract][Full Text] [Related]
39. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.
Chase TN; Engber TM; Mouradian MM
Neurology; 1994 Jul; 44(7 Suppl 6):S15-8. PubMed ID: 7519334
[TBL] [Abstract][Full Text] [Related]
40. [Pergolide: a useful agonist for the treatment of Parkinson disease].
Bonnet AM; Houeto JL
Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
